60 likes | 171 Vues
Explore the impact of ACE inhibitors, ARBs, and statins on COPD risk in high- and low-risk cohorts. Detailed risk ratios and demographics analysis from a significant study in cardiology.
E N D
ACE inhibitors, ARBs and Statins in COPD:High- and Low-Risk Cohorts G. B. John Mancini, et al. J Am Coll Cardiol 2006;47:2554-60
ACE inhibitors, ARBs and Statins in COPD:Demographics of Cases and Controls in the High-Risk Cohort G. B. John Mancini, et al. J Am Coll Cardiol 2006;47:2554-60
ACE inhibitors, ARBs and Statins in COPD:Demographics of Cases and Controls in the Low-Risk Cohort G. B. John Mancini, et al. J Am Coll Cardiol 2006;47:2554-60
ACE inhibitors, ARBs and Statins in COPD:Unadjusted Risk Ratios and 95% Confidence Intervals in the High- and Low-Risk COPD Cohorts G. B. John Mancini, et al. J Am Coll Cardiol 2006;47:2554-60
ACE inhibitors, ARBs and Statins in COPD:Fully adjusted risk ratios and 95% Confidence Intervals in the High-Risk COPD Cohorts G. B. John Mancini, et al. J Am Coll Cardiol 2006;47:2554-60
ACE inhibitors, ARBs and Statins in COPD:Fully adjusted risk ratios and 95% Confidence Intervals in the Low-Risk COPD Cohorts G. B. John Mancini, et al. J Am Coll Cardiol 2006;47:2554-60